Singapore, Nov. 5 -- SciRhom GmbH, a therapeutic antibody company, announced on 5 Nov 2019 its development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signalling pathways, including TNF-alpha signalling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.

iRhom2 is a protein that controls the tumour necrosis factor-alpha-convertase (TACE; also known as ADAM17), a set of molecular scissors that activates several crucial signalling pathways, including TNF-alpha (...